Libor Havel
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 24
- Lung Cancer Diagnosis and Treatment 22
- Brain Metastases and Treatment 2
- Oncology 30
- Lung Cancer Research Studies 16
- Cancer Immunotherapy and Biomarkers 14
- Global Cancer Incidence and Screening 1
- Co-authors
- Lubos B. Petruzelka (5 shared papers)Petr Zatloukal (5 shared papers)Milada Zemanová (6 shared papers)A Kubík (3 shared papers)Evzen Krepela (2 shared papers)Filip Jankú (1 shared paper)Pavel Fiala (1 shared paper)Ladislav Pecen (1 shared paper)
- Journals
- Annals of Oncology (12 papers)Lung Cancer (6 papers)The Lancet Oncology (6 papers)New England Journal of Medicine (4 papers)ESMO Open (3 papers)
- Partner nations
- CzechiaUnited StatesUnited Kingdom
In The Last Decade
Libor Havel
51 papers receiving 21k citations
Libor Havel's Hit Papers
Peers
Comparison fields: 5 of 104
- Oncology 14.9k
- Pulmonary and Respiratory Medicine 5.7k
- Immunology 853
- Cancer Research 566
- Radiology, Nuclear Medicine and Imaging 444
Countries citing papers authored by Libor Havel
This map shows the geographic impact of Libor Havel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libor Havel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libor Havel more than expected).
Fields of papers citing papers by Libor Havel
This network shows the impact of papers produced by Libor Havel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libor Havel. The network helps show where Libor Havel may publish in the future.
Co-authors
The 25 scholars most cited alongside Libor Havel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 7161 |
| 2 | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 2722 |
| 3 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2712 |
| 4 | First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 2105 |
| 5 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1737 |
| 6 | Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Hit paper breakdown → | 2022 | 541 |
| 7 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 522 |
| 8 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 498 |
| 9 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2013 | 455 |
| 10 | 2016 | 440 | |
| 11 | 2016 | 413 | |
| 12 | 2004 | 359 | |
| 13 | Perioperative Nivolumab in Resectable Lung Cancer Hit paper breakdown → | 2024 | 299 |
| 14 | Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN Hit paper breakdown → | 2022 | 242 |
| 15 | 2003 | 140 | |
| 16 | 2023 | 98 | |
| 17 | 2023 | 80 | |
| 18 | 2023 | 78 | |
| 19 | 2022 | 58 | |
| 20 | 2004 | 55 |
About Libor Havel
Libor Havel is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Immunology, Biophysics and Physiology, having authored 55 papers that have together received 21.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Diagnosis and Treatment (22 papers), Lung Cancer Research Studies (16 papers), Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (3 papers), Brain Metastases and Treatment (2 papers), Smoking Behavior and Cessation (1 paper) and Global Cancer Incidence and Screening (1 paper). The work is most often cited by research in Oncology (14.9k citations), Pulmonary and Respiratory Medicine (5.7k citations), Immunology (853 citations), Cancer Research (566 citations) and Radiology, Nuclear Medicine and Imaging (444 citations). Libor Havel has collaborated with scholars based in Czechia, United States and United Kingdom. Frequent co-authors include Lubos B. Petruzelka, Petr Zatloukal, Milada Zemanová, A Kubík, Evzen Krepela, Filip Jankú, Pavel Fiala, Ladislav Pecen, Libor Judas and Yi-Long Wu. Their work appears in journals such as Annals of Oncology, Lung Cancer, The Lancet Oncology, New England Journal of Medicine and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.